Rhemotoid arthritis opd tretmemt

Reading File
Finding Sources
Finding Sources
Searching PubMed

"Rheumatoid Arthritis"[MeSH Terms] AND treatment

Searching the Web

rheumatoid arthritis outpatient management guideline DMARD methotrexate referral NICE

Rheumatoid arthritis (RA) OPD treatment plan
RA should be managed early by a rheumatologist, because joint damage can occur within months. The goal is remission or low disease activity using a treat-to-target plan, with regular assessment of swollen joints, pain, function, ESR/CRP, and medication toxicity. NICE RA guidance recommends rapid specialist referral for suspected persistent inflammatory arthritis.

1. At the OPD visit

  • Confirm diagnosis and disease activity: joint examination, ESR/CRP, CBC, liver and kidney function.
  • Tests often needed before DMARDs: rheumatoid factor, anti-CCP, hepatitis B/C, TB screening if biologic/JAK therapy may be used, pregnancy test where relevant.
  • X-ray or ultrasound of affected hands/feet or other joints, as appropriate.
  • Assess comorbidities: infection risk, lung disease, liver disease, renal disease, cardiovascular risk, vaccinations.

2. Medicines

A. Pain and short-term inflammation control
  • NSAID such as naproxen or ibuprofen may reduce pain and stiffness, if safe for the patient.
  • Use the lowest effective dose and consider stomach protection if indicated.
  • Avoid or use great caution with kidney disease, peptic ulcer/bleeding, anticoagulants, uncontrolled hypertension, or heart failure.
  • Short course corticosteroid tablets or an injection into a joint may be used as a temporary “bridge” while DMARDs begin working. Long-term steroid use should generally be avoided due to diabetes, osteoporosis, infection, cataract, and other risks.
B. Disease-modifying treatment, the main treatment These prevent joint damage. They must be started and monitored by an experienced clinician.
  • Methotrexate is commonly first choice, often with folic acid.
  • If unsuitable: sulfasalazine, leflunomide, or hydroxychloroquine may be options.
  • If control is inadequate, the specialist may use combinations or advance to:
    • Biologic DMARDs: TNF inhibitors, abatacept, tocilizumab, rituximab, etc.
    • Targeted synthetic DMARDs: JAK inhibitors such as tofacitinib, baricitinib, upadacitinib, depending on eligibility and risk profile.
NICE recommends conventional DMARD treatment with escalation toward remission or low activity; biologic or targeted therapy is generally combined with methotrexate if it is tolerated. NICE treatment recommendations

3. Monitoring

  • CBC, liver function, kidney function, ESR/CRP at intervals decided by the clinician, especially after starting or changing DMARDs.
  • Review disease activity monthly until controlled, then less often.
  • Do not stop methotrexate, leflunomide, biologics, or steroids suddenly without medical advice.
  • Avoid live vaccines while significantly immunosuppressed. Keep influenza, pneumococcal, COVID-19, and other routine vaccines up to date.

4. Non-drug OPD advice

  • Physiotherapy and occupational therapy.
  • Daily gentle range-of-motion and strengthening exercises.
  • Regular low-impact activity: walking, cycling, swimming.
  • Stop smoking, maintain healthy weight, adequate sleep.
  • Joint protection, splints or assistive devices when needed.
  • Calcium/vitamin D and bone protection assessment if steroids are used.

Seek urgent medical care now if

  • Fever, chills, or feeling severely unwell while on DMARDs/biologics.
  • A single joint becomes suddenly very hot, red, swollen, and extremely painful. Septic arthritis must be excluded.
  • Shortness of breath, chest pain, coughing blood.
  • Pregnancy or possible pregnancy while taking methotrexate or leflunomide.
Important: treatment choice and doses depend on age, pregnancy plans, liver/kidney tests, infections, other medicines, and disease severity. Do not self-start methotrexate or steroids. A recent systematic-review search found no reason to replace early DMARD-based care, though newer agents continue to evolve (PMIDs: 39939220, 41357870).
This is a shared conversation. Sign in to Orris to start your own chat.